KBC Group’s TG Therapeutics TGTX Stock Holding History

KBC Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$254K	Sell	4,547 -788	-15%	-$42.6K	﹤0.01%	936
2026 Q2	$293K	Hold	5,335	–	–	﹤0.01%	921
2026 Q1	$177K	Buy	5,335 +1,195	+29%	+$35.6K	﹤0.01%	1022
2025 Q4	$123K	Hold	4,140	–	–	﹤0.01%	1155
2025 Q3	$150K	Hold	4,140	–	–	﹤0.01%	1034
2025 Q2	$149K	Sell	4,140 -2,887	-41%	-$107K	﹤0.01%	989
2025 Q1	$277K	Buy	7,027 +67	+1%	+$2.25K	﹤0.01%	904
2024 Q4	$209K	Buy	6,960 +2,285	+49%	+$65.6K	﹤0.01%	1103
2024 Q3	$109K	Buy	4,675 +1,092	+30%	+$23.8K	﹤0.01%	1236
2024 Q2	$64K	Buy	3,583 +437	+14%	+$6.97K	﹤0.01%	1468
2024 Q1	$48K	Hold	3,146	–	–	﹤0.01%	1586
2023 Q4	$54K	Hold	3,146	–	–	﹤0.01%	1475
2023 Q3	$26K	Buy	+3,146	New	+$43.9K	﹤0.01%	1844

Other funds holding TGTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

KBC Group's TGTX Position: Q3 2026 in Review

KBC Group reduced its TG Therapeutics (TGTX) stake by 15% in Q3 2026, selling an estimated $42.6K and leaving 4,547 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #936.

KBC Group first reported a position in TGTX in Q3 2023 and has held it in 13 quarters since. The position peaked at $293K in Q2 2026. 197 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

KBC Group held 4,547 shares of TG Therapeutics worth $254K as of Q3 2026.
KBC Group sold 788 TG Therapeutics shares in Q3 2026, an estimated $42.6K.
TG Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #936 holding.
KBC Group first reported a position in TG Therapeutics in Q3 2023 and has held it in 13 quarters since.
KBC Group's TG Therapeutics position peaked at $293K in Q2 2026.
197 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.